Pediatrics. Eastern Europe

Fibrosis, vol. 7, no 4, pp. 267–269. 
28. Hebestreit A. (2007) Hypertonic saline inhibits luminal sodium channels in respiratory epithelium. 
European Journal of Applied Physiology, vol. 100, no 2, pp. 177–183. 
29. Global Initiative for Asthma: Revised, 2014. Available at: www.ginaasthma.org
30. Global Initiative for Asthma: Revised, 2018. Available at: www.ginaasthma.org
31. Joos G. (2000) Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. 
Chest Dis., no 55 (5), pp. 411–414.
32. O’Sullivan B. (2009) The clinical approach to lung disease in patients with cystic fibrosis. Seminars 
in Respiratory and Critical Care Medicine, vol. 30, no 5, pp. 505–513. 
33. Reeves E.P. (2011) Nebulized hypertonic saline decreases IL-8 in sputum of patients with cystic 
fibrosis. American Journal of Respiratory and Critical Care Medicine, vol. 183, no 11, pp. 1517–1523. 
34. Zhang L. (2013) Nebulised hypertonic saline solution for acute bronchiolitis in infants (Review). 
The Cochrane Library. Issue 7. Available at: http://www.thecochranelibrary.com
35. Zamani M. (2016) Sravnenie effektivnosti ventolina i gipertonicheskogo solevogo rastvora (3%) 
pri lechenii ostrogo bronhiolita u detei [Comparison of effectiveness of ventolin and hypertonic 
saline (3%) in treatment of acute bronchiolitis in children]. Astma ta alergіya, no 1, pp. 20. 
36. Zhang L. (2013) Nebulised hypertonic saline solution for acute bronchiolitis in infants (Review). 
The Cochrane Library, Issue 7.
_________________________________
Поступила/Received: 15.09.2018
Контакты/Contacts: [e-mail]